Anna Lena Fisse1, Kalliopi Pitarokoili2, Jens Kuhle3, Min-Suk Yoon4, David Leppert3, Jeremias Motte2, Xiomara Pedreiturria2, Ludwig Kappos3, Ralf Gold2. 1. Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany. Anna.Fisse@rub.de. 2. Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany. 3. Departments of Medicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Basel, Switzerland. 4. Department of Neurology, Evangelisches Krankenhaus Hattingen, Hattingen, Germany.
Abstract
OBJECTIVE: Neurofilament light chain (NfL) in serum indicates neuro-axonal damage in diseases of the central and peripheral nervous system. Reliable markers to enable early estimation of clinical outcome of intensive care unit (ICU) patients are lacking. The aim of this study was to investigate, whether serum NfL levels are a possible biomarker for prediction of outcome of ICU patients. METHODS: Thirty five patients were prospectively examined from admission to ICU until discharge from the hospital or death. NfL levels were measured longitudinally by a Simoa assay. RESULTS: NfL was elevated in all ICU patients and reached its maximum at day 35 of ICU treatment. Outcome determined by modified Rankin Scale at the end of the follow-up period correlated with NfL level at admission, especially in the group of patients with impairment of the central nervous system (n = 25, r = 0.56, p = 0.02). CONCLUSION: NfL could be used as a prognostic marker for outcome of ICU patients, especially in patients with impairment of the central nervous system.
OBJECTIVE:Neurofilament light chain (NfL) in serum indicates neuro-axonal damage in diseases of the central and peripheral nervous system. Reliable markers to enable early estimation of clinical outcome of intensive care unit (ICU) patients are lacking. The aim of this study was to investigate, whether serum NfL levels are a possible biomarker for prediction of outcome of ICU patients. METHODS: Thirty five patients were prospectively examined from admission to ICU until discharge from the hospital or death. NfL levels were measured longitudinally by a Simoa assay. RESULTS:NfL was elevated in all ICU patients and reached its maximum at day 35 of ICU treatment. Outcome determined by modified Rankin Scale at the end of the follow-up period correlated with NfL level at admission, especially in the group of patients with impairment of the central nervous system (n = 25, r = 0.56, p = 0.02). CONCLUSION:NfL could be used as a prognostic marker for outcome of ICU patients, especially in patients with impairment of the central nervous system.
Entities:
Keywords:
Critical illness polyneuromyopathy; Intensive care unit; Neurofilament; Outcome
Authors: Gwen G A van Lieverloo; Luuk Wieske; Camiel Verhamme; Alexander F J Vrancken; Pieter A van Doorn; Zuzanna Michalak; Christian Barro; Ivo N van Schaik; Jens Kuhle; Filip Eftimov Journal: J Peripher Nerv Syst Date: 2019-04-29 Impact factor: 3.494
Authors: Lise Beier Havdal; Lise Lund Berven; Joel Selvakumar; Tonje Stiansen-Sonerud; Truls Michael Leegaard; Trygve Tjade; Henrik Zetterberg; Kaj Blennow; Vegard Bruun Bratholm Wyller Journal: Front Neurol Date: 2022-06-22 Impact factor: 4.086
Authors: Nora Chekrouni; Thijs M van Soest; Matthijs C Brouwer; Eline A J Willemse; Charlotte E Teunissen; Diederik van de Beek Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-12-13
Authors: Patrick J Smeele; Lisa Vermunt; Siebe Blok; Jan Willem Duitman; Esther J Nossent; Michiel A van Agtmael; Leo M A Heunks; Janneke Horn; Harm Jan Bogaard; Charlotte E Teunissen Journal: Brain Commun Date: 2022-07-26